Trials / Completed
CompletedNCT00058552
A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer
A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced, Refractory or Recurrent Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 129 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced ovarian cancer that is refractory to, or has recurred following, prior chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pertuzumab (rhuMAb 2C4) |
Timeline
- Start date
- 2003-05-01
- Primary completion
- 2004-07-01
- Completion
- 2004-07-01
- First posted
- 2003-04-09
- Last updated
- 2017-03-08
- Results posted
- 2015-06-23
Source: ClinicalTrials.gov record NCT00058552. Inclusion in this directory is not an endorsement.